Advanced search
Publication Cover
International Journal of Neuroscience Volume 127, 2017 - Issue 3
Submit an article Journal homepage
2,471
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations

Neil B. HampsonVirginia Mason Medical Center, Seattle, WA, USACorrespondence[email protected]
View further author information
,
Karl D. KieburtzClintrex LLC, Rye, NY, USAView further author information
,
Peter A. LeWittDepartment of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, West Bloomfield, MI, USAView further author information
,
Mika Leinonen4Pharma AB, Stockholm, SwedenView further author information
&
Martin I. FreedAcorda Therapeutics, Chelsea, MA, USAView further author information
Pages 276-284 | Received 23 Nov 2015, Accepted 23 May 2016, Published online: 27 Jun 2016

References

  • Sabate M, Gonzalez I, Ruperez F, et al. Obstructive and restrictive pulmonary dysfunctions in Parkinson’s disease. J Neurol Sci 1996;138(1–2):114–9.
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427–42.
  • Brown LK. Respiratory dysfunction in Parkinson’s disease. Clin Chest Med 1994;15(4):715–27.
  • Shill H, Stacy M. Respiratory function in Parkinson’s disease. Clin Neurosci 1998;5(2):131–5.
  • Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Resp J 2005;26(2):319–38.
  • Vincken WG, Gauthier SG, Dolfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders; a cause of airflow limitation. N Engl J Med 1984;311(7):438–42.
  • Hovestadt A, Bogaard JM, Meerwaldt JD, et al. Pulmonary function in Parkinson’s disease. J Neurol Neurosurg Psychiatr 1989;52(3):329–33.
  • Izquierdo-Alonso JL, Jiménez-Jiménez FJ, Cabrera-Valdivia F, et al. Airway dysfunction in patients with Parkinson’s disease. Lung 1994;172(1):47–55.
  • Herer B, Arnulf I, Housset B. Effects of levodopa on pulmonary function in Parkinson’s disease. Chest 2001;119(2):387–93.
  • Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trends Neurosci 2000;23(Suppl):S2–S7.
  • Freed MI, Batycky R, Merica E. Safety, tolerability, and pharmacokinetics following inhaled administration of CVT-301, a levodopa powder, aerosol, in healthy adult subjects. Mov Disord 2013;28(Suppl 1):S154.
  • Freed MI, Grosset DG, Worth PF, et al. Rapid levodopa augmentation following inhaled CVT-301 results in rapid improvement in motor response when administered to PD patients in the OFF state. Neurology 2014;82(10 Suppl):S7.007.
  • LeWitt P, Saint-Hillaire M-H, Grosset DG, et al. Inhaled levodopa (CVT-301) provides rapid improvement of OFF states in Parkinson’s disease. Poster Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, 2015 June 14–18, San Diego, CA [Poster 260].
  • LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26611.
  • Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force Report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19(9):1020–8.
  • Fahn S, Elton RL. UPDRS program members. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson’s disease. Volume 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153–63.
  • Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a general sample of the U.S. population. Am J Respir Crit Care Med 1999;169(1):179–87.
  • Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–98.
  • Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the Unified Parkinson’s Disease Rating Scale. Arch Neurol 2010;67(1):64–70.
  • Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present and future. Eur Respir J 2010;36(1):12–9.
  • Lim A, Leow L, Huckabee M, et al. A pilot study of swallowing and respiration in Parkinson’s disease: “on” and “off” levodopa. Dysphagia 2008;23(1):76–81.
  • Polatli M, Akyol A, Cildag O, et al. Pulmonary function tests in Parkinson’s disease. Eur J Neurol 2001;8(4):341–5.
  • De Pandis MF, Starace A, Stefanelli F, et al. Modification of respiratory function parameters in patients with severe Parkinson’s disease. Neurol Sci 2002;23(Suppl 2):S69–70.
  • Pal PK, Sathyaprabha TN, Tuhina P, et al. Pattern of subclinical pulmonary dysfunctions in Parkinson’s disease and the effect of levodopa. Mov Disord 2007;22(3):420–4.
  • Seccombe LM, Giddings HL, Rogers PG, et al. Abnormal ventilatory control in Parkinson’s disease—further evidence for non-motor dysfunction. Respir Physiol Neurobiol 2011;179(2–3):300–4.
  • Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948–68.
  • Sanches VS, Santos FM, Fernandes JM, et al. Neurodegenerative disorders increase decline in respiratory muscle strength in older adults. Respir Care 2014;59(12):1838–45.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.